The global Blood Based Biomarker market is expanding rapidly, driven by rising demand for early disease detection and precision medicine. In 2024, the market is valued at USD 9.6 billion and is projected to reach USD 28.4 billion by 2033, growing at a CAGR of 12.9%. Over 68% of clinical trials now incorporate biomarker-based endpoints, highlighting their critical role in modern...